Compounds that increase or mimic cyclic adenosine monophosphate enhance tristetraprolin degradation in lipopolysaccharide-treated murine J774 macrophages

Journal of Pharmacology and Experimental Therapeutics

Volumn 326, Issue 2, 2008, Pages 514-522

  Jalonen, Ulla ^a   Paukkeri, Erja Leena ^a   Moilanen, Eeva ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 8 BROMO CYCLIC AMP; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BUCLADESINE; CYCLIC AMP; CYCLIC AMP DERIVATIVE; FORSKOLIN; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; LACTACYSTIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEASOME INHIBITOR; SALBUTAMOL; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA;

3' UNTRANSLATED REGION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; INFLAMMATION; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA BINDING; RNA STABILITY; WESTERN BLOTTING;

ADRENERGIC BETA-AGONISTS; ANIMALS; CELL LINE; CYCLIC AMP; FORSKOLIN; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTEASOME ENDOPEPTIDASE COMPLEX; RECEPTORS, ADRENERGIC, BETA-2; RNA, MESSENGER; TIME FACTORS; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 47949116256     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.133702     Document Type: Article

References (40)

1. Blackshear PJ (2002) Tristetraprolin and other CCCH tandem zinc-finger proteins in the regulation of mRNA turnover. Biochem Soc Trans 30:945-952.
2. Bouchard L, Tchernof A, Deshaies Y, Marceau S, Lescelleur O, Biron S, and Vohl MC (2007) ZFP36: a promising candidate gene for obesity-related metabolic complications identified by converging genomics. Obes Surg 17:372-382.
3. Brook M, Tchen CR, Santalucia T, McIlrath J, Arthur JSC, Saklatvala J, and Clark AR (2006) Posttranslational regulation of tristetraprolin subcellular localization and protein stability by p38 mitogen-activated protein kinase and extracellular signal-regulated kinase pathways. Mol Cell Biol 26:2408-2418.
4. Cao H, Kelly MA, Kari F, Dawson HD, Urban JF Jr, Coves S, Roussel AM, and Anderson RA (2007a) Green tea increases anti-inflammatory tristetraprolin and decreases pro-inflammatory tumor necrosis factor mRNA levels in rats. J Inflamm 4:1.
5. Cao H, Polansky MM, and Anderson RA (2007b) Cinnamon extract and polyphenols affect the expression of tristetraprolin, insulin receptor, and glucose transporter 4 in mouse 3T3-L1 adipocytes. Arch Biochem Biophys 459:214-222.
6. Cao H, Tuttle JS, and Blackshear PJ (2004) Immunological characterization of tristetraprolin as a low abundance, inducible, stable cytosolic protein. J Biol Chem 279:21489-21499.
7. Carballo E, Lai WS, and Blackshear PJ (2000) Evidence that tristetraprolin is a physiological regulator of granulocyte-macrophage colony-stimulating factor messenger RNA deadenylation and stability. Blood 95:1891-1899.
8. Carballo E, Lai WS, and Blackshear PJ (1998) Feedback inhibition of macrophage tumor necrosis factor-α production by tristetraprolin. Science 281:1001-1005.
9. Carrick DM and Blackshear PJ (2007) Comparative expression of tristetraprolin (TTP) family member transcripts in normal human tissues and cancer cell lines. Arch Biochem Biophys 462:278-285.
10. Chang X, Fan Y, Karyala S, Schwemberger S, Tomlinson CR, Sartor MA, and Puga A (2007) Ligand-independent regulation of transforming growth factor β1 expression and cell cycle progression by the aryl hydrocarbon receptor. Mol Cell Biol 27:6127-6139.
11. Chen CY, Gherzi R, Ong SE, Chan EL, Raijmakers R, Pruijn GJM, Stoecklin G, Moroni C, Mann M, and Karin M (2001) AU binding proteins recruit the exosome to degrade ARE-containing mRNAs. Cell 107:451-464.
12. 178, a site required for 14-3-3 binding. J Biol Chem 279:10176-10184.
13. Deleault KM, Skinner SJ, and Brooks SA (2008) Tristetraprolin regulates TNF-α mRNA stability via a proteasome dependent mechanism involving the combined action of the ERK and p38 pathways. Mol Immunol 45:13-24.
14. MAPK/MK2 cascade. J Immunol 178:2813-2826.
15. Franks TM and Lykke-Andersen J (2007) TTP and BRF proteins nucleate processing body formation to silence mRNAs with AU-rich elements. Genes Dev 21:719-735.
16. Frasca D, Landin AM, Alvarez JP, Blackshear PJ, Riley RL, and Blomberg BB (2007) Tristetraprolin, a negative regulator of mRNA stability, is increased in old B cells and is involved in the degradation of E47 mRNA. J Immunol 179:918-927.
17. Hitti E, Iakovleva T, Brook M, Deppenmeier S, Gruber AD, Radzioch D, Clark AR, Blackshear PJ, Kotlyarov A, and Gaestel M (2006) Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol 26:2399-2407.
18. Jalonen U, Lahti A, Korhonen R, Kankaanranta H, and Moilanen E (2005) Inhibition of tristetraprolin expression by dexamethasone in activated macrophages. Biochem Pharmacol 69:733-740.
19. Jalonen U, Leppänen T, Kankaanranta H, and Moilanen E (2007) Salbutamol increases tristetraprolin expression in macrophages. Life Sci 81:1651-1658.
20. Jalonen U, Nieminen R, Vuolteenaho K, Kankaanranta H, and Moilanen E (2006) Down-regulation of tristetraprolin expression results in enhanced IL-12 and MIP-2 production and reduced MIP-3α synthesis in activated macrophages. Mediators Inflamm 2006:40691.
21. Jing Q, Huang S, Guth S, Zarubin T, Motoyama A, Chen J, Di Padova F, Lin SC, Gram H, and Han J (2005) Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell 120:623-634.
22. Johnson BA, Stehn JR, Yaffe MB, and Blackwell TK (2002) Cytoplasmic localization of tristetraprolin involves 14-3-3-dependent and -independent mechanisms. J Biol Chem 277:18029-18036.
23. Lai WS and Blackshear PJ (2001) Interactions of CCCH zinc finger proteins with mRNA: tristetraprolin-mediated AU-rich element-dependent mRNA degradation can occur in the absence of a poly(A) tail. J Biol Chem 276:23144-23154.
24. Lai WS, Carballo E, Strum JR, Kennington EA, Phillips RS, and Blackshear PJ (1999) Evidence that tristetraprolin binds to AU-rich elements and promotes the deadenylation and destabilization of tumor necrosis factor alpha mRNA. Mol Cell Biol 19:4311-4323.
25. Laroia G, Cuesta R, Brewer G, and Schneider RJ (1999) Control of mRNA decay by heat shock-ubiquitin-proteasome pathway. Science 284:499-502.
26. Linker K, Pautz A, Fechir M, Hubrich T, Greeve J, and Kleinert H (2005) Involvement of KSRP in the post-transcriptional regulation of human iNOS expression-complex interplay of KSRP with TTP and HUR. Nucleic Acids Res 33:4813-4827.
27. Mahtani KR, Brook M, Dean JL, Sully G, Saklatvala J, and Clark AR (2001) Mitogen-activated protein kinase p38 controls the expression and posttranslational modification of tristetraprolin, a regulator of tumor necrosis factor alpha mRNA stability. Mol Cell Biol 21:6461-6469.
28. Ogilvie RL, Abelson M, Hau HH, Vlasova I, Blackshear PJ, and Bohjanen PR (2005) Tristetraprolin down-regulates IL-2 gene expression through AU-rich element-mediated mRNA decay. J Immunol 174:953-961.
29. Phillips K, Kedersha N, Shen L, Blackshear PJ, and Anderson P (2004) Arthritis suppressor genes TIA-1 and TTP dampen the expression of tumor necrosis factor α, cyclooxygenase 2, and inflammatory arthritis. Proc Natl Acad Sci U S A 101: 2011-2016.
30. Rigby WF, Roy K, Collins J, Rigby S, Connolly JE, Bloch DB, and Brooks SA (2005) Structure/function analysis of tristetraprolin (TTP): p38 stress-activated protein kinase and lipopolysaccharide stimulation do not alter TTP function. J Immunol 174:7883-7893.
31. Sauer I, Schaljo B, Vogl C, Gattermeier I, Kolbe T, Müller M, Blackshear PJ, and Kovarik P (2006) Interferons limit inflammatory responses by induction of tristetraprolin. Blood 107:4790-4797.
32. Sawaoka H, Dixon DA, Oates JA, and Boutaud O (2003) Tristetraprolin binds to the 3′-untranslated region of cyclooxygenase-2 mRNA. A polyadenylation variant in a cancer cell line lacks the binding site. J Biol Chem 278:13928-13935.
33. 2- adrenergic receptors in inflammation and allergy. Curr Drug Targets Inflamm Allergy 4:157-162.
34. Smoak K and Cidlowski JA (2006) Glucocorticoids regulate tristetraprolin synthesis and posttranscriptionally regulate tumor necrosis factor alpha inflammatory signaling. Mol Cell Biol 26:9126-9135.
35. Stoecklin G and Anderson P (2007) In a tight spot: ARE-mRNAs at processing bodies. Genes Dev 21:627-631.
36. Stoecklin G, Ming XF, Looser R, and Moroni C (2000) Somatic mRNA turnover mutants implicate tristetraprolin in the interleukin-3 mRNA degradation pathway. Mol Cell Biol 20:3753-3763.
37. Stoecklin G, Stoeckle P, Lu M, Muehlemann O, and Moroni C (2001) Cellular mutants define a common mRNA degradation pathway targeting cytokine AU-rich elements. RNA 7:1578-1588.
38. Stoecklin G, Stubbs T, Kedersha N, Wax S, Rigby WFC, Blackwell TK, and Anderson P (2004) MK2-induced tristetraprolin: 14-3-3 complexes prevent stress granule association and ARE-mRNA decay. EMBO J 23:1313-1324.
39. Taylor GA, Carballo E, Lee DM, Lai WS, Thompson MJ, Patel DD, Schenkman DI, Gilkeson GS, Broxmeyer HE, Haynes BF, et al. (1996) A pathogenetic role for TNFα in the syndrome of cachexia, arthritis, and autoimmunity resulting from tristetraprolin (TTP) deficiency. Immunity 4:445-454.
40. Zhang F, Hu Y, Huang P, Toleman CA, Paterson AJ, and Kudlow JE (2007) Proteasome function is regulated by cyclic AMP-dependent protein kinase through phosphorylation of Rpt6. J Biol Chem 282:22460-22471.